Zetagen Therapeutics, a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced the successful closure of its Series B1 financing round of $12,908,000. The round was 100% oversubscribed, reflecting strong investor confidence in the company's proprietary Zeta Platform and its potential to transform breast cancer care..

Zetagen Therapeutics是一家私营的临床阶段生物制药公司，率先开发针对转移性乳腺癌和原发性乳腺癌的首创瘤内治疗方法，今天宣布成功完成了12,908,000美元的B1轮融资。本轮超额认购达100%，反映了投资者对公司专有的Zeta平台及其在乳腺癌治疗领域的潜力充满信心。

The funding round closed with strong demand from private investors-led by JSTAR Capital Investments-demonstrating deep confidence in our clinical efficacy.

这轮融资在私人投资者的强烈需求下成功结束，由JSTAR资本投资公司领投，充分展示了对我们临床疗效的深厚信心。

Zetagen has three novel drugs in development with the Zeta Platform, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results.

Zetagen公司利用Zeta平台正在开发三种新型药物：用于治疗乳腺癌骨转移的ZetaMet™（Zeta-BC-003）、用于乳腺癌肝转移（BCLM）的ZetaMast™（Zeta-MBC-005），以及用于治疗原发性HR+乳腺癌的ZetaPrime™（Zeta-PBC-007），所有药物均取得了令人鼓舞的结果。

To learn more, visit www.zetagen.com. The entire Zeta platform is designed for intratumoral administration to reduce off-target toxicity, utilizing proprietary carriers-some incorporating our New Molecular Entity. The USPTO has granted Zetagen Composition-of-Matter patents and claims for all three therapeutics..

要了解更多信息，请访问www.zetagen.com。整个Zeta平台旨在通过瘤内给药以减少脱靶毒性，利用专有载体，部分结合了我们的新分子实体。美国专利商标局已授予Zetagen关于所有三种治疗药物的物质组成专利及权利要求。